Description
The B-Cell Precursor Acute Lymphoblastic Leukemia Minimal Residual Disease (BCP-ALL-MRD) kit is intended for flow-cytometric qualitative and semi-quantitative identification and discrimination of normal/ reactive B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) cells in bone marrow specimens from treated BCP-ALL patients.
| Description | Quantity/Size | Part Number | EntrezGene ID |
|---|---|---|---|
| Lyophilized Antibody Combination Tube 1 | 5 Tests (4 ea) | CYT-BCP-ALL-MRD-T1-V | N/A |
| Lyophilized Antibody Combination Tube 2 | 5 Tests (4 ea) | CYT-BCP-ALL-MRD-T2-V | N/A |
| CD34-PerCP-Cyanine5.5 Compensation | 1 Test (1 ea) | CYT-BCP-ALL-MRD-CD34 | 947 |
| CD19-PE-Cyanine7 Compensation | 1 Test (1 ea) | CYT-BCP-ALL-MRD-CD19 | N/A |
| CD38-APC-C750™ Compensation | 1 Test (1 ea) | CYT-BCP-ALL-MRD-CD38 | N/A |
| CD45-OC515™ Compensation | 1 Test (1 ea) | CYT-BCP-ALL-MRD-CD45 | N/A |
| Fixative-free ammonium chloride erythrocyte lysing solution 10X (Bulklysis™) | 20 Tests (1 ea) | CYT-BCP-ALL-MRD-BL | N/A |
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostics Use.
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.